A phase Ila clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild -type p53 and MDM2 amplification or MDM2/CDK4 co-amplification

被引：0
|
作者：
Meric-Bernstam, F. [1 ]
Somaiah, N. [2 ]
DuBois, S. G. [3 ,4 ]
Dumbrava, E. E. Ileana [1 ]
Shapiro, G. I. [4 ]
Patel, M. R. [5 ]
Goel, S. [6 ]
Bauer, T. [7 ]
Pinchasik, D. [8 ]
Annis, A. [9 ]
Aivado, M. [10 ]
Vukovic, V. [11 ]
Saleh, M. [12 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Sarcoma Med Oncol, Houston, TX 77030 USA
[3] Dana Farber & Boston Childrens, Pediat Oncol, Boston, MA USA
[4] Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA
[5] Florida Canc Specialists & Res Inst, Med Oncol, Sarasota, FL USA
[6] Montefiore Med Ctr, Med Oncol, Eastchester Albert Einstein Canc Ctr, East Campus,Med Pk, New York, NY USA
[7] Sarah Cannon Res Inst, Drug Dev, Nashville, TN USA
[8] Aileron Therapeut Inc, Clin Dev, Cambridge, MA USA
[9] Aileron Therapeut Inc, Res, Watertown, MA USA
[10] Aileron Therapeut Inc, Res & Drug Dev, Watertown, MA USA
[11] Aileron Therapeut Inc, Clin & Med, Watertown, MA USA
[12] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Hematol Oncol, Birmingham, AL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
475P
引用
收藏
页码：179 / +
页数：2
相关论文
共 50 条
  • [41] A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma
    Langenberg, M. H.
    Gluck, L.
    Weger, V.
    Frank, R.
    Eskens, F.
    Blay, J. Y.
    Soria, J. C.
    Chawla, S.
    Gounder, M.
    Wagner, A.
    Zhang, Y.
    Kambuj, P.
    Loberg, R.
    Henary, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S34 - S34
  • [42] Effect of P53 activation through targeting MDM2/MDM4 heterodimer on Tregulatory and effector cells in the peripheral blood of type 1 diabetes patients
    Fierabracci, A.
    Pellegrino, M.
    Traversi, G.
    Cappa, M.
    Rosado, M. M.
    Moretti, F.
    DIABETOLOGIA, 2019, 62 : S226 - S226
  • [43] Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
    Mitobe, Yuta
    Suzuki, Shuhei
    Nakagawa-Saito, Yurika
    Togashi, Keita
    Sugai, Asuka
    Sonoda, Yukihiko
    Kitanaka, Chifumi
    Okada, Masashi
    CANCERS, 2023, 15 (17)
  • [44] Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients
    Pellegrino, Marsha
    Traversi, Gianandrea
    Arena, Andrea
    Cappa, Marco
    Rosado, M. Manuela
    Andreani, Marco
    Delfino, Domenico, V
    Moretti, Fabiola
    Fierabracci, Alessandra
    PLOS ONE, 2020, 15 (01):
  • [45] Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma
    Payton, M.
    Pinchasik, D.
    Mehta, A.
    Goel, S.
    Zain, J. M.
    Sokol, L.
    Jacobsen, E.
    Patel, M. R.
    Horwitz, S. M.
    Meric-Bernstam, F.
    Shustov, A.
    Weinstock, D.
    Aivado, M.
    Annis, D. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST)
    Somaiah, Neeta
    Van Tine, Brian Andrew
    Chmielowski, Bartosz
    Drabick, Joseph J.
    Chawla, Sant P.
    McKean, Meredith
    Spira, Alexander I.
    O'Byrne, Kenneth John
    Foresto, Steven A.
    Movva, Sujana
    Kim, AeRang
    Gastman, Brian
    Pressey, Joseph Gerald
    Paudyal, Ben
    De, Asit
    Winkler, Robert E.
    Li, Mingyu
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material:: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas
    Hostein, I
    Pelmus, M
    Aurias, A
    Pedeutour, F
    Mathoulln-Pélissier, S
    Coindre, JM
    JOURNAL OF PATHOLOGY, 2004, 202 (01): : 95 - 102
  • [48] p53 mutation and absence of mdm2 amplification and Ki-ras mutation in 4-hydroxyamino quinoline 1-oxide induced transplantable osteosarcomas in rats
    Kido, A
    Tsujiuchi, T
    Tsutsumi, M
    Takahama, M
    Okajima, E
    Kobitsu, K
    Miyauchi, Y
    Mii, Y
    Tamai, S
    Konishi, Y
    CANCER LETTERS, 1997, 112 (01) : 5 - 10
  • [49] Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.
    Swiecicki, Paul
    Tang, Yuefen
    Pearson, Alexander T.
    Muzaffar, Jameel
    Fidler, Mary J.
    Winkler, Robert
    Fu, Tommy
    Li, Mingyu
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of Concept, Phase Ib Study
    Razak, Albiruni R. Abdul
    Bauer, Sebastian
    Suarez, Cristina
    Lin, Chia-Chi
    Quek, Richard
    Huetter-Kroenke, Marie Luise
    Cubedo, Ricardo
    Ferretti, Stephane
    Guerreiro, Nelson
    Jullion, Astrid
    Orlando, Elena J.
    Clementi, Giorgia
    Dejmek, Janna Sand
    Halilovic, Ensar
    Fabre, Claire
    Blay, Jean-Yves
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1087 - 1097
12345